Home›Drug Pipeline› Targeted Therapies May Shift COPD Care Toward Precision Medicine
Targeted Therapies May Shift COPD Care Toward Precision MedicineTargeted Therapies Offer New Options for Chronic Obstructive Pulmonary Disease
Frontiers in MedicinePublished September 13, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider emerging COPD targeted therapies investigational; no efficacy or safety data reported.
This systematic review summarizes emerging targeted therapies for chronic obstructive pulmonary disease (COPD), including monoclonal antibodies, small-molecule modulators, and stem cell-based therapies, and contrasts them with conventional bronchodilator and inhaled corticosteroid management. The authors frame the field as transitioning from symptom-oriented care toward precision medicine and mechanism-based interventions.
Conventional therapies are described as effectively relieving symptoms and reducing exacerbation frequency. Emerging targeted therapies are characterized as offering promising therapeutic opportunities, particularly for patients with corticosteroid resistance and frequent exacerbations. The review does not report pooled effect sizes, absolute numbers, p-values, or confidence intervals for any outcome.
Safety data are not reported, including adverse events, serious adverse events, discontinuations, and tolerability. The review also does not report sample size, setting, follow-up duration, or funding and conflicts of interest. No limitations are listed by the authors.
The review explicitly notes that it summarizes potential opportunities and does not provide clinical trial data for specific outcomes or safety profiles. Clinicians should interpret these findings as hypothesis-generating rather than practice-changing. The proposed shift toward precision medicine in COPD remains investigational, and current management should continue to rely on established therapies with proven efficacy and safety profiles.
How this fits prior evidence
This review extends prior coverage of COPD management by shifting focus from established therapies to investigational targeted approaches. Prior coverage noted that triple therapy improves SGRQ scores but increases pneumonia risk compared to dual bronchodilation, and that skeletal muscle dysfunction is linked to impaired exercise capacity and higher exacerbation risk. The review's emphasis on corticosteroid resistance and frequent exacerbations aligns with the recognized heterogeneity of COPD, but it does not provide the comparative effectiveness or safety data needed to position emerging therapies against established regimens. It addresses a gap in precision medicine for COPD while remaining consistent with prior evidence that conventional therapies retain a central role.
This review looked at how different treatments work for people living with Chronic Obstructive Pulmonary Disease (COPD). While standard treatments like bronchodilators and inhaled corticosteroids are currently used to manage symptoms and reduce the number of flare-ups, some patients do not get enough relief from these common options.
Researchers identified emerging targeted therapies, including monoclonal antibodies and small-molecule modulators, as promising alternatives. These treatments are especially interesting for patients who have frequent flare-ups or who do not respond well to standard corticosteroids. These new options focus on specific biological mechanisms rather than just general symptom relief.
Because this is a systematic review of available evidence rather than a clinical trial, it does not provide specific data on safety or exact success rates for each drug. It highlights a shift toward precision medicine for COPD. Patients should talk to their doctors to see if these newer, targeted options are appropriate for their specific condition.
What this means for you:
Targeted therapies may offer new hope for COPD patients who do not respond well to standard treatments.
Common questions
What are the current standard treatments for COPD?
The standard treatments for COPD currently include bronchodilators and inhaled corticosteroids. These medications are used to help manage daily symptoms and reduce the frequency of flare-ups for patients with the condition.
Who might benefit from these new targeted therapies?
These emerging therapies, such as monoclonal antibodies and small-molecule modulators, are particularly promising for patients who have frequent flare-ups or who have shown resistance to standard corticosteroid treatments.
How do these new treatments differ from standard ones?
While standard treatments focus on general symptom relief, these new targeted therapies represent a move toward precision medicine. They are designed to target specific mechanisms of the disease to provide more tailored care.
Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic inflammatory disorder of the airways characterized by substantial morbidity, disability, and mortality. It poses a significant global public health burden. Conventional therapies for COPD, which mainly rely on bronchodilators and inhaled corticosteroids, effectively relieve symptoms and reduce exacerbation frequency in patients. However, their clinical utility is limited by safety concerns and heterogeneous treatment responses across disease phenotypes. Moreover, these therapeutic approaches cannot halt or reverse disease progression. With increasing understanding of the complex molecular and cellular mechanisms underlying COPD pathogenesis, therapeutic approaches are evolving from conventional symptom-oriented management toward precision medicine and mechanism-based targeted interventions. This review systematically summarizes recent advances in emerging targeted therapies for COPD, including monoclonal antibodies directed against key inflammatory pathways, small-molecule modulators targeting core pathogenic mechanisms, and stem cell-based therapies. By selectively modulating critical processes involved in chronic inflammation, tissue injury, and airway remodeling, these novel therapeutic strategies offer promising therapeutic opportunities, particularly for patients with corticosteroid resistance and frequent exacerbations.
